The purpose of this task order is to perform a short-term physical and chemical compatibility (PC) study on the antigen and MF59 dosing combinations to support of the intended hold time for the…
Ended Awarded Last action
- Contract number
- 75A50124F61011
- Awardee
-
Seqirus Inc. UEI Z6N1LJ2RD6E3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $23,670
Award facts
- Contract value 100% obligated
- $23,670.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Holly Springs, NC, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Original award | $23,670 |
About this award
The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $23.7K delivery order to Seqirus Inc. on September 30, 2024, to conduct a short-term physical and chemical compatibility study on antigen and MF59 dosing combinations in support of the BARDA-sponsored BPI-23-001 study. The work will be performed at Seqirus's manufacturing facility in Holly Springs, North Carolina, with an ultimate completion date of March 14, 2025. This delivery order is issued under Seqirus's existing $13.4 billion Indefinite Delivery Contract with HHS ASPR, awarded in February 2022, which serves as the primary vehicle for rapid procurement of medical countermeasures and pandemic preparedness initiatives.
Seqirus Inc., a division of CSL Seqirus, is a leading developer and manufacturer of vaccines and medical countermeasures, with particular expertise in influenza and emerging infectious disease preparedness. The contract carries a firm fixed-price structure with no set-aside designation. Under the parent IDC, HHS ASPR has issued over $116 million in task orders covering vaccine production, antigen procurement, clinical research, and stockpile maintenance. This compatibility study represents the type of specialized research support that Seqirus regularly provides to advance pandemic preparedness capabilities and support vaccine development programs for potential public health emergencies.
Description
The purpose of this task order is to perform a short-term physical and chemical compatibility (PC) study on the antigen and MF59 dosing combinations to support of the intended hold time for the barda sponsored BPI-23-001 study.
Quick answers
Who was awarded contract 75A50124F61011?
75A50124F61011 was awarded to Seqirus Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2024.
How much is contract 75A50124F61011 worth?
The government has obligated $23,670 on 75A50124F61011.
Is contract 75A50124F61011 an order under another contract?
Yes. 75A50124F61011 is a delivery order under 75A50122D00004, an indefinite delivery contract.
Was contract 75A50124F61011 competed?
The extent of competition for 75A50124F61011 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award